SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018 - Rakuten Medical

1.0Rakuten Medical - To conquer cancer.https://rakuten-med.com/usSUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018 - Rakuten Medical - To conquer cancer.rich600338<blockquote class="wp-embedded-content" data-secret="CDvEQ4GQVw"><a href="https://rakuten-med.com/us/news/press-releases/2018/01/16/388/">SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://rakuten-med.com/us/news/press-releases/2018/01/16/388/embed/#?secret=CDvEQ4GQVw" width="600" height="338" title="“SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018” — Rakuten Medical - To conquer cancer." data-secret="CDvEQ4GQVw" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://rakuten-med.com/us/wp-includes/js/wp-embed.min.js /* ]]> */ </script> Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that […]https://rakuten-med.com/us/wp-content/uploads/sites/6/2021/02/RakutenMedical_KV.png1500900